%20LIMITED%2002-May-2008_files/image002.jpg){kind=small}
MIRA
INFORM REPORT
|
Report Date : |
02.05.2008 |
IDENTIFICATION
DETAILS
|
Name : |
NAWAN
LABORATORIES (PRIVATE) LIMITED |
|
|
|
|
Registered Office : |
136 - 138, Sector 15, Korangi Industrial
Area, Karachi |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
1995 |
|
|
|
|
Com. Reg. No.: |
0034937 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture and Marketing of Pharmaceutical
Products |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Business Name
NAWAN LABORATORIES
(PRIVATE) LIMITED
Full Address
|
Registered Address & Factory |
|
136 - 138,
Sector 15, Korangi Industrial Area, Karachi, Pakistan |
|
Tel |
92 (21) 5065835 - 37 (3
Lines) |
|
Fax |
92
(21) 5061936 |
|
Email |
Short Description Of Business
|
Nature of Business |
Manufacture
& Marketing of Pharmaceutical Products |
|
Year Established |
1995 |
|
Registration # |
0034937 |
Branches
In Lahore at present
Auditors
Mehmood Idrees Qamar & Co.
(Chartered Accountants)
103-104, Amber Estate, Shahrah-e-Faisal,
Karachi, Pakistan
Legal Status
Subject Company was established as a Private
Limited Company in 1995
|
Authorized
Capital |
Rs. 10,000,000/-
divided into 100,000 shares of Rs. 100/- each |
|
Issued & Paid
up Capital |
Rs. 10,000,000/-
divided into 100,000 shares of Rs. 100/- each |
Details of Chief Executive/
Directors
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Naseer Ahmed Awan Mr. Talat Naseer Awan Mr. Ehsan Naseer Awan |
Pakistani Pakistani Pakistani |
64 Khayaban-e-Janbaz, Phase V, D.H.A.,
Karachi 64 Khayaban-e-Janbaz, Phase V, D.H.A.,
Karachi 64 Khayaban-e-Janbaz, Phase V, D.H.A.,
Karachi |
Business Business Business |
Chief Executive Director Director |
Shareholders
|
Names |
No. of Shares |
|
Mr. Naseer Ahmed Awan Mr. Talat Naseer Awan Mr. Ehsan Naseer Awan |
80,000 10,000 10,000 |
Associates
A. Subsidiary
None
B. Associated Companies
(1) Nawan
Trading Corporation, Pakistan.
Products / Services
Manufacture &
marketing of Pharmaceutical Products by its brand name including AMLOWAN, ASPIWAN, AZIROMYCIN, CEFAWAN,
CEFORIN, DICLOWAN, FAMOWAN, LEXIWAN, LOMIVAC, LORESTIN, NAFRADIN, NAMOXIL,
NAWAZIN, NAWAZOLE, OLTRIX, VISCODIN
Number of Employees
145
Trade Suppliers (Foreign)
HEBEI HUARI PHARMACEUTICAL CO. LTD, CHINA.
ZHUHAI
UNITED LABORATORIES CO., LTD, CHINA.
Annual Production Volume
The capacity and
production of the company’s plant is indeterminable as it involves varying
processes of manufacture.
Annual Sales Volume
|
Year |
In Pak Rupees |
|
2006 |
100,000,000/-
(Estimated) |
Distributorship Network
Mainly in Lahore,
Karachi & Rawalpindi
Bankers
Bank Alhabib
Limited, Pakistan.
Habib Bank
Limited, Pakistan.
Soneri Bank
Limited, Pakistan.
Memberships
Pakistan Pharmaceutical Manufacturers
Association.(PPMA)
Korangi Association of Trade &
Industry.(KATI)
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 65.70 |
|
UK Pound |
1 |
Rs. 130.40 |
|
Euro |
1 |
Rs. 102.40 |
Comments
Subject Company was established in 1995 and
is engaged in manufacture & marketing of Pharmaceutical Products. Overall
reputation is satisfactory. Trade relations are reported as fair. The Company
can be considered for normal business dealings at usual trade terms &
conditions.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)